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DITORIAL
ewborn  screening  for sickle  cell  disease:  necessary
ut not  sufﬁcient,
riagem  neonatal  para  veriﬁcar  a  existência  de  doenc¸a falciforme:
ecessária,  porém  insuﬁciente
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ickle  cell  disease  is  a  global  health  problem  that
ffects  >  300,000  newborns  per  year,  predominantly  in  Sub-
aharan  Africa,1 where  mortality  is  estimated  to  be  >  50%
y  age  5  years  for  those  with  homozygous  hemoglobin  S
HbSS).1 In  Brazil,  there  are  estimated  to  be  >  30,000  indi-
iduals  with  sickle  cell  disease  and  2,500  newborns  per
ear,  making  this  the  most  common  genetic  disorder  in  the
ountry.2 Advances  in  the  management  of  sickle  cell  dis-
ase  in  the  United  States  have  led  to  a  decline  in  mortality
rom  about  26%  to  approximately  1-2%  in  the  ﬁrst  18  years  of
ife,  with  the  greatest  progress  demonstrated  by  a  ﬂatten-
ng  of  the  mortality  peak  in  the  ages  of  1-4  years  from  13%
o  2%.3,4 Much  of  this  progress  resulted  from  the  implemen-
ation  of  universal  newborn  screening  in  all  50  states  in  the
.S.  following  publication  of  the  results  of  the  prophylactic
enicillin  study,  which  demonstrated  a  dramatic  reduction
n  sepsis  and  mortality  due  to  S.  pneumonia  in  the  ﬁrst  ﬁve
ears  of  life.5
Remarkable  progress  has  also  occurred  in  Brazil  over  the
ast  two  decades,  during  which  newborn  hemoglobinopathy
creening  was  initiated  in  Campinas  (1992),  Minas  Gerais
1998),  Rio  de  Janeiro  (2001),  Pernambuco  (2003),  and
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ther  locations.6--9 This  expansion  of  neonatal  screening
as  promoted  by  a  decree  from  the  Brazilian  Ministry
f  Health  in  2001,  calling  for  a  multi-phased  imple-
entation  of  screening  for  congenital  disorders  including
emoglobinopathies.  This  effort  resulted  in  a  report  in  2010
escribing  the  remarkable  heterogeneity  in  the  prevalence
f  sickle  cell  trait  (HbAS,  1.1-9.8%)  and  sickle  cell  ane-
ia  (HbSS,  2.2-172/100,000  population)  in  different  regions
f  the  country.2 The  report  from  the  Federal  University
f  Minas  Gerais  in  Belo  Horizonte  by  Sabarense  et  al.  in
his  issue  of  the  Journal  updates  the  results  of  neonatal
emoglobinopathy  screening  in  this  state.10 Disappointingly,
he  authors  found  no  signiﬁcant  difference  between  the
ortality  rate  in  children  born  between  March  of  1998  and
ebruary  of  2005  (5.4%)  and  those  born  between  March  of
005  and  February  of  2012  (5.1%)  (p  =  0.72).  Characteris-
ics  of  the  193  children  who  died  in  the  combined  period
1998-2012)  included:  residence  in  smaller  towns,  age  less
han  2  years  (56.5%),  median  age  at  death  1.7  years,  22%  of
eaths  occurring  outside  of  the  hospital  (at  home  or  while  in
ransit),  and  remarkably  low  socioeconomic  status  of  fam-
lies  (91.6%  monthly  per  capita  income  ≤  minimum  wage.
n  the  ﬁrst  period,  72%  of  the  deaths  occurred  before  age
 years,  compared  with  77%  in  the  second  period.  Overall,
he  major  causes  of  mortality  were  infection  (including  sep-
icemia,  acute  chest  syndrome,  and  gastroenteritis,  45%),
‘indeterminate’’  perhaps  due  to  a  lack  of  awareness  of  the
nderlying  diagnosis  (28%),  and  acute  splenic  sequestration
14%).  Although  it  is  not  clear  from  the  data  as  presented,
 substantial  portion  of  the  infectious  deaths  were  related
o  ‘‘pneumonia/acute  chest  syndrome’’,  which  was  also  the
er Editora Ltda. All rights reserved.
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Table  1  Plan  of  care  for  infants  with  sickle  cell  disease  in  ﬁrst  year  of  life.a
Age  Topics
1  month  Conﬁrmation  of  hemoglobinopathy  diagnosis,  introduction  to  sickle  cell  disease,  preliminary  education
regarding prophylactic  penicillin  administration  and  fever  management.
2-3 months  Review  of  hemoglobinopathy  genotype  and  family  studies;  discussion  of  sickle  cell  pathophysiology;
discussions  regarding  immunizations,  penicillin  prophylaxis,  and  fever;  initial  education  regarding  splenic
sequestration.
5-6 months Review  of  adherence  with  penicillin  prophylaxis,  education  about  spleen  palpation,  provision  of  information
about therapy  options  (hydroxyurea,  chronic  transfusion,  bone  marrow  transplant)  and  research.
8-9 months  Review  of  adherence  with  penicillin  prophylaxis,  review  of  spleen  palpation,  discussion  about  dactylitis  and
pain events.
12  months  Discussion  about  acute  chest  syndrome,  discussion  about  hydroxyurea  (and  potential  initiation  of  treatment).
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da Excerpted from standard approach used at St. Jude Children’s
leading  cause  of  mortality  in  the  report  from  the  HEMORIO
Center  in  Rio  de  Janeiro.11 No  recording  of  the  terms  ‘‘sickle
cell  disease’’  or  ‘‘sickle  cell  anemia’’  as  a  cause  of  death  was
found  in  46%  of  the  death  certiﬁcates.  Mortality  occurred
within  the  ﬁrst  24  hours  in  more  than  40%  of  patients.  In
the  later  time  period,  there  was  a  slight  reduction  in  the
proportion  of  patients  whose  death  occurred  at  home  or  in
transit,  and  a  slight  increase  in  the  death  certiﬁcates  which
mentioned  the  term  ‘‘sickle  cell’’.  Overall,  the  unchanged
mortality  rate  in  the  ﬁrst  ﬁve  years  of  life,  and  the  contin-
ued  occurrence  of  infection  and  splenic  sequestration  as  the
major  causes  of  mortality,  indicated  that  newborn  screening
for  sickle  cell  disease,  even  when  performed  in  a  compre-
hensive  and  effective  manner,  was  insufﬁcient  by  itself  to
greatly  modify  the  course  of  the  disease.
What  can  be  done  to  improve  mortality  in  developing
countries  around  the  globe,  in  which  increasing  resources
and  interventions  for  the  care  of  persons  with  sickle  cell  dis-
ease  are  becoming  available?  Sabarense  et  al.  suggested  that
‘‘social  and  economic  development’’  in  Minas  Gerais  was
necessary  to  change  the  scenario.10 Consideration  should
be  given  to  several  areas  in  which  preventive  care  for
children  with  sickle  cell  disease  and  education  of  families
may  be  improved.  In  September  of  2014,  the  Expert  Panel
guidelines  (Evidence-Based  Management  of  Sickle  Cell  Dis-
ease)  from  the  National  Heart,  Lung,  and  Blood  Institute
of  the  U.S.  National  Institutes  of  Health  were  published.12
These  included  recommendations  in  the  areas  of  peni-
cillin  prophylaxis,  pneumococcal  immunization,  appropriate
response  to  fever,  recognition  and  management  of  acute
splenic  sequestration,  and  prevention  of  stroke  through
transcranial  Doppler  ultrasonography  (TCD)  screening.  For
example,  the  panel  had  strong  recommendations  for  the
prevention  of  invasive  pneumococcal  infection,  including
the  administration  of  oral  penicillin  prophylaxis  for  all  chil-
dren  with  HbSS  at  least  until  age  5,  vaccination  against
pneumococcus  for  sickle  cell  patients  of  all  ages,  includ-
ing  a  detailed  vaccination  schedule  for  PCV13  (Prevnar13)
and  PPSV23  (Pneumovax),  and  education  of  families  and
caregivers  about  the  necessity  to  seek  immediate  medical
attention  whenever  signiﬁcant  fever  (temperature  >  38.5 ◦C)
occurs.  These  guidelines  also  made  strong  recommenda-
tions  about  the  need  for  screening  for  increased  stroke  risk
through  TCD  examinations  according  to  a  speciﬁed  sched-
ule.  In  the  management  of  acute  splenic  sequestration,  the
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uidelines  acknowledged  that  there  were  no  randomized
linical  trials  to  provide  an  evidence  base,  but  the  need
or  education  of  families  and  healthcare  providers  regarding
ecognition  of  the  symptomatology  associated  with  splenic
equestration  and  the  necessity  for  emergent  management
as  emphasized.
How  can  these  recommendations  be  translated  into
omprehensive  and  consistent  practice  that  will  lead  to
iminished  mortality  in  Minas  Gerais  and  other  regions
round  the  globe  with  similar  sickle  cell  populations  and
ealthcare  resources?  One  approach  is  to  utilize  a  plan  of
are  for  sickle  cell  disease,  which  details  the  expectations  at
ach  clinic  visit  according  to  the  age  of  the  patient,  thereby
reating  standardized  expectations  for  both  families  and
ealthcare  providers.  For  example,  at  our  institution  infants
ith  sickle  cell  disease  are  managed  with  the  goals  in  the
able  1  (among  other  goals)  when  they  are  seen  at  routine
linic  appointments  in  the  ﬁrst  year  of  life.
An  important  recommendation  of  the  Expert  Panel  report
alls  for  increased  use  of  hydroxyurea.  Recent  long-term
ollow-up  reports  of  adult  patients  with  sickle  cell  ane-
ia  from  the  U.S.  Multi-center  Study  of  Hydroxyurea  (MSH)
nd  the  LaSHS  study  (Laikon  Study  of  Hydroxyurea  in  Sickle
ell  Syndromes)  in  Greece  have  shown  substantial  reduc-
ion  in  mortality  related  to  the  use  of  this  drug.13,14 More
imilar  to  the  population  described  by  Sabarense  et  al.10 is
he  cohort  from  Rio  de  Janeiro,  which  included  1,760  sub-
ects,  ages  3-18  years,  267  of  whom  received  hydroxyurea
or  a  median  of  two  years.11 Survival  among  the  children
reated  with  hydroxyurea  was  signiﬁcantly  greater  than
mong  the  untreated  (99.5  vs.  94.5%,  p  =  0.01),  primarily  due
o  fewer  deaths  from  acute  chest  syndrome  and  infection,
nd  these  patients  had  signiﬁcantly  fewer  hospitalizations
nd  emergency  room  visits.  Toxicity  was  predominantly
ild,  reversible  neutropenia.  It  was  concluded  that  hydrox-
urea  reduces  morbidity  and  is  associated  with  decreased
ortality  in  children  with  sickle  cell  disease.  All  three
f  the  above  studies  were  retrospective,  but  the  BABY
UG  study  (Pediatric  Hydroxyurea  Phase  III  Clinical  Trial),  a
ulti-center  prospective  randomized  double-blinded  trial,
emonstrated  that  infants  receiving  hydroxyurea  had  sub-
tantial  clinical  beneﬁt  from  reduction  of  pain,  dactylitis,
cute  chest  syndrome,  hospitalization,  and  transfusion,  as
ell  as  signiﬁcant  increases  in  hemoglobin,  mean  corpuscu-
ar  volume  (MCV),  and  hemoglobin  F  levels.15 In  part  due
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o  these  data,  the  recommendation  of  the  Expert  Panel
as:  ‘‘In  infants  9  months  of  age  and  older,  children,  and
dolescents  with  sickle  cell  anemia,  offer  treatment  with
ydroxyurea  regardless  of  clinical  severity  to  reduce  SCD-
elated  complications  (e.g.,  pain,  dactylitis,  acute  chest
yndrome,  anemia)’’.  This  was  a  ‘‘strong’’  recommendation
ith  ‘‘high  quality  evidence’’  for  ages  9-42  months,  and
 ‘‘moderate  recommendation’’  with  ‘‘moderate  quality
vidence’’  for  children  greater  than  42  months  and  ado-
escents.  Of  note,  the  panel  intentionally  used  the  term
‘offer’’,  realizing  that  the  patients’  and  their  caretakers’
alues  and  preferences  may  differ  particularly  consider-
ng  treatment  burden  (e.g.,  laboratory  monitoring,  ofﬁce
isits),  availability  of  drug  in  a  liquid  form,  and  cost.  There-
ore,  the  panel  strongly  encouraged  shared  decision-making
nd  discussion  of  hydroxyurea  therapy  with  all  patients
nd  families.  In  addition,  the  Expert  Panel  provided  a
onsensus  treatment  protocol  for  the  implementation  of
ydroxyurea  therapy.  This  recommendation,  in  conjunction
ith  the  data,  albeit  retrospective,  from  HEMORIO,  suggest
hat  hydroxyurea  could  have  a  major  long-term  beneﬁt  in
ecreasing  mortality  in  children  with  sickle  cell  disease  in
inas  Gerais,  as  well  as  in  other  regions  of  the  world  where
ickle  cell  healthcare  is  developing.  Of  course,  there  remain
umerous  barriers  that  must  be  overcome  to  accomplish
idespread  and  proper  utilization  of  hydroxyurea  treat-
ent,  including  providing  appropriate  education  to  both
ealthcare  providers  and  families  regarding  the  beneﬁts  and
isks  of  the  drug,  the  availability  of  clinics  and  laboratories
hat  can  provide  the  necessary  infrastructure  for  regular
valuation  of  patients  on  treatment,  and  adequate  ﬁnan-
ial  support  from  the  Health  Ministry  and  other  sources.
ne  incentive  for  government  support  of  the  expanded  use
f  hydroxyurea  is  the  cost  savings  that  result,  primarily
hrough  decreased  hospitalization,  which  more  than  offsets
he  increased  cost  of  outpatient  management  and  the  cost
f  the  drug  itself.16 In  addition,  there  remain  questions  to
e  addressed  regarding  the  use  of  hydroxyurea  in  children
ith  sickle  cell  disease,  such  as  whether  a  ﬁxed  dose  of  the
rug  (at  20  mg/kg/day)  or  an  escalation  to  maximum  toler-
ted  dose  (MTD)  provides  a  greater  beneﬁt-risk  ratio.17 An
dditional  consideration  might  be  ‘‘low  dose’’  hydroxyurea,
hich  might  require  less  monitoring  in  a  resource-limited
nvironment.18
Can  the  approaches  described  above  make  a  difference?
t  will  be  interesting  to  see  the  data  on  mortality  in  children
ith  sickle  cell  disease  in  Minas  Gerais  in  another  ten  years.
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